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Introduction: Serum uric acid (UA) has been known to have a positive association with blood pressure (BP).
However, the relationship between serum UA and BP in different age groups is unclear.
Methods: A total of 45,098 Koreans who underwent health examinations at Korea Association of Health Promotion
with no history of taking drugs related with UA and/or BP were analyzed for determining the relationship between
serum UA and BP.
Results: In men <40, serum UA was significantly associated with systolic (β = 0.25, p = 0.002) and diastolic BP (β = 0.41,
p < 0.001) after adjustment for age, diabetes, dyslipidemia, body mass index, and estimated glomerular filtration rate.
Men between ages 40 and 59 showed similar results regarding diastolic BP. The association between serum UA and BP
was stronger in women <40 (β = 0.54, p < 0.001 for systolic BP; β = 0.65, p < 0.001 for diastolic BP) and in between 40
and 59 (β = 0.51, p < 0.001 for diastolic BP). The association was not significant in men and women ≥60. The odds
ratios (ORs) of hyperuricemia for hypertension were 1.25 (95% confidence interval [CI], 1.08 to 1.45; p = 0.003) and 1.33
(95% CI, 1.11 to 1.60; p = 0.002) in men <40 and in between 40 and 59, respectively, in the multivariate analysis. The OR
was 2.60 (95% CI, 1.37 to 4.94; p = 0.0034) in women <40. The relationship between hyperuricemia and hypertension
was not significant in other age/gender groups.
Discussion: In contrast to the elderly of 60 and over, the non-elderly showed significant associations between serum
UA and BP.
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Hypertension in adults is the most common form of car-
diovascular diseases. The prevalence of hypertension
grows higher with aging, resulting in an increase in mor-
bidity and mortality through various events such as
myocardial infarction, heart failure, stroke, and renal
failure [1-4].
Hyperuricemia has been proposed to have an associ-
ation with hypertension in various studies. Serum uric
acid (UA) levels were demonstrated to be an independent
predictor for developing hypertension [5-7]. Regardless
of the different ethnic origins, a continuous relationship* Correspondence: withnoel@empal.com
1Cardiovascular Center, Korea University Guro Hospital, 148 Gurodong-ro,
Guro-gu, 152-703 Seoul, South Korea
Full list of author information is available at the end of the article
© 2015 Lee et al. This is an Open Access artic
(http://creativecommons.org/licenses/by/4.0),
provided the original work is properly credited
creativecommons.org/publicdomain/zero/1.0/between serum UA and blood pressure (BP) was ob-
served in African-Americans and whites [8,9] as well as
in Asians [7,10] including Koreans [11-13]. For determin-
ing the causal role of serum UA in the development of
hypertension, Mazzali et al. [14] demonstrated an eleva-
tion in serum UA followed by an increase in BP via a
crystal-independent mechanism in rat models. Reduction
of serum UA was associated with a decrease in BP
through the regulation of renin-angiotensin and nitric
oxide system [15].
Taking this into account, a hypothesis regarding the ef-
fect of serum UA-lowering agents which could have
potential benefits in prevention and treatment of hyper-
tension has emerged. Feig and Johnson [1] showed a
high correlation between serum UA and BP in childhood
primary hypertension and demonstrated promising resultsle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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adolescents with newly developed hypertension in a pilot
study [16]. Early intervention of controlling serum UA
was proposed to have effect on delaying the progression of
early hypertension. However, studies specifically of elderly
patients have had controversial results regarding the rela-
tion between serum UA and BP [17,18]. Also, the use of
UA-lowering agents did not have effect on controlling BP
in the elderly as in the adolescents [19]. Taken together,
the relationship between serum UA and BP was known to
be weakened by the aging process, but there were no stud-
ies confirming in which age group the relationship would
be the strongest.
Also, studies mentioned above lack control over vari-
ables which could have effect on serum UA levels such
as the history of taking diuretics, antihypertensive medi-
cation or other drugs, obesity, and renal function. More-
over, some of them were performed with only a small
number of subjects.
On the basis of the considerations above, we per-
formed the present study to compare the relationship
between serum UA and BP or hypertension by different
age groups in a single large cohort with adjustment of
all possible confounding factors. This study may identify
a more specific target group in which the association be-
tween serum UA and BP or hypertension is the highest
and controlling serum UA would have maximal benefit.
Methods
Subjects
A total of 91,882 subjects who underwent health examina-
tions at Korea Association of Health Promotion (KAHP)
during January, 2005 to December, 2009 were initially en-
rolled. Patients lacking at least 6 months of medical his-
tory in the Health Insurance Review and Assessment
Service (HIRA) system were excluded. Informed consent
was obtained according to the Helsinki Declaration for all
of the enrolled patients in our study, and the studyFigure 1 Flow diagram of the study protocol. *Non-antihypertensive medi
allopurinol, benzbromarone, colchicine, febuxostat, rasburicase, probenecid
nicotinic acid. KAHP, Korea Association of Health Promotion; HIRA, Health Inprotocol was approved by the institutional review boards
of KAHP, HIRA, and Korea University.
Subjects with a history of taking antihypertensive and/
or medications which could affect serum UA levels were
also excluded. A flow diagram of the study protocol and
medications for exclusion are presented in Figure 1. A
total of 45,098 subjects were included in the final ana-
lysis. To evaluate the relationship between serum UA
and BP in different ages, we divided the subjects into
three groups by age; <40, 40–59, and ≥60. In each group,
comparison between gender differences was done also.
Baseline measurements and definitions
Systolic and diastolic BP were measured in all of the
subjects. The diagnosis of hypertension was based on a
systolic BP of 140 mmHg or higher and a diastolic BP of
90 mmHg or higher. Height and weight were measured
and body mass index (BMI) was calculated as the weight
in kilograms (kg) divided by the square of the height in
meters (m). Previous diagnoses which could affect serum
UA levels, such as diabetes, chronic kidney disease, dys-
lipidemia, were thoroughly investigated. Fasting blood
sugar levels, estimated glomerular filtration rate (eGFR),
and lipid profiles including total cholesterol, triglyceride,
high-density lipoprotein, and low density lipoprotein
were checked for the evaluation of comorbidities. His-
tory of hospital admissions and previous medications
were also taken through a cohort established between
the network of KAHP and HIRA. Hyperuricemia was di-
agnosed in men and women each with a serum UA level
over 7.0 mg/dL and 6.0 mg/dL [20].
Statistical analysis
All statistical analyses were performed using the SAS
ver. 9.3 (SAS Institute Inc., Cary, NC, USA). Significance
testing of the difference between means was done by an in-
dependent Student’s t-test, and correlations were assessed
by Pearson coefficients. Analysis of covariance was usedcations which could affect serum UA levels were excluded including
, diuretics, ethambutol, cyclosporine, diazoxide, aspirin, levodopa, and
surance Review and Assessment Service; UA, uric acid.
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ear and logistic regression modeling to distinguish each of
the contributions of age, diabetes, dyslipidemia, BMI, and
eGFR to the effect of UA on BP and hyperuricemia on
hypertension. All continuous variables were expressed as
means ± standard deviation. A p value of <0.05 was con-
sidered statistically significant, but to compensate the po-
tential of an alpha error generating from the stratified
analysis regarding age and gender (a total of six groups)
in the multiple linear and logistic regression model,
Bonferroni correction was applied and a p value of 0.05/
6 was considered statistically significant.
Results
A total of 45,098 subjects were included in the final ana-
lysis. Baseline characteristics of the subjects divided into
three groups by age are presented in Table 1. Mean age
and BMI of the total subjects were 39.0 ± 11.6 kg/m2
and 23.2 ± 3.4 kg/m2 each. Systolic BP was significantly
higher in group ≥60 compared to the other groups
(126.6 ± 15.3 mmHg vs. 114.7 ± 12.8 mmHg, 120.2 ±
14.2 mmHg, p < 0.001). Comparison of diastolic BP be-
tween the three groups also showed similar results (76.3 ±
9.7 mmHg vs. 70.8 ± 8.9 mmHg, 74.8 ± 9.9 mmHg; p <
0.001). The prevalence of comorbidities such as hyperten-




Age (years) 39.0 ± 11.6
Height (cm) 165.6 ± 8.7
Weight (kg) 63.9 ± 12.6
Body mass index (kg/m2) 23.2 ± 3.4
Systolic blood pressure (mmHg) 117.1 ± 13.9
Diastolic blood pressure (mmHg) 72.3 ± 9.5
Uric acid (mg/dL) 5.2 ± 1.5
Fasting blood sugar (mg/dL) 91.3 ± 17.7
Estimated glomerular filtration rate (mL/min/1.73 m2) 88.0 ± 27.1
Total cholesterol (mg/dL) 180.2 ± 33.8
High-density lipoprotein (mg/dL) 52.0 ± 10.2
Triglyceride (mg/dL) 105.6 ± 82.5
Low density lipoprotein (mg/dL) 107.1 ± 29.3
Hypertension 3,122 (6.9)
Diabetes mellitus 1,224 (2.7)
Dyslipidemia 10,073 (22.3)
Hyperuricemia 5,700 (12.6)
Values are presented as number (%) or mean ± standard deviation.
All p values in the post hoc analysis comparing each group in all the variables werewhereas the prevalence of hyperuricemia was highest in
group <40. Nearly twice as many subjects were diagnosed
with hypertension in hyperuricemic subjects than nor-
mouricemic subjects (12% vs. 6%, p < 0.001) (Figure 2).
The comparison of serum UA levels of hypertensive sub-
jects in different age/gender groups are presented in
Figure 3. Serum UA levels were significantly higher in sub-
jects with hypertension among all the age/gender groups
except ≥60.
According to the multivariate linear regression analysis
between serum UA and BP, in men <40, serum UA was
significantly associated with systolic (β = 0.25, p = 0.002)
and diastolic BP (β = 0.41, p < 0.001) after adjustment for
age, diabetes, dyslipidemia, BMI, and eGFR. However,
men between the age 40 and 59 showed similar results
regarding only diastolic BP (β = 0.43, p < 0.001). The as-
sociation between serum UA and BP was stronger in
women <40 (β = 0.54, p < 0.001 for systolic BP; β = 0.65,
p < 0.001 for diastolic BP) and in between 40 and 59 re-
garding diastolic BP (β = 0.51, p < 0.001). The association
was not significant in men and women ≥60 (Table 2).
After performing multiple logistic regression analysis,
the odds ratios (ORs) of hyperuricemia for hypertension
were 1.25 (95% confidence interval [CI], 1.08 to 1.45; p =
0.003) and 1.33 (95% CI, 1.11 to 1.60; p = 0.002) each in







15,212 (52.7) 7,089 (54.0) 1,730 (55.5) <0.001
31.7 ± 4.9 48.7 ± 5.5 65.0 ± 4.2 <0.001
167.2 ± 8.5 163.5 ± 8.3 160.0 ± 8.6 <0.001
64.3 ± 13.7 63.7 ± 10.2 60.5 ± 9.5 <0.001
22.9 ± 3.7 23.7 ± 2.8 23.6 ± 2.9 <0.001
114.7 ± 12.8 120.2 ± 14.2 126.6 ± 15.3 <0.001
70.8 ± 8.9 74.8 ± 9.9 76.3 ± 9.7 <0.001
5.3 ± 1.5 5.1 ± 1.4* 5.1 ± 1.3* <0.001
89.3 ± 14.6 94.4 ± 20.1 96.6 ± 21.4 <0.001
91.2 ± 28.0 83.1 ± 24.6 78.4 ± 23.4 <0.001
174.2 ± 31.3 189.9 ± 33.7 194.4 ± 34.4 <0.001
52.1 ± 10.0* 51.8 ± 10.4† 52.0 ± 10.4*,† 0.046
100.1 ± 62.2 115.4 ± 67.0 115.3 ± 60.0 <0.001
102.3 ± 27.2 115.0 ± 30.7 117.3 ± 31.2 <0.001
1,144 (3.9) 1,377 (10.5) 601 (19.3) <0.001
344 (1.2) 625 (4.8) 255 (8.2) <0.001
5,330 (18.5) 3,752 (28.6) 991 (31.8) <0.001
4,104 (14.2) 1,296 (9.9) 300 (9.6) <0.001
under 0.05 except the groups indicated as same letters like * or †.
Figure 2 Prevalence of hypertension in hyperuricemia. A significant difference between normouricemic and hyperuricemic patients was seen
among the total subjects who were enrolled (p < 0.05).
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tionship between hyperuricemia and hypertension was not
significant in other age/gender groups (Table 3).
Discussion
The major findings in the present study enable us to
identify the importance of age in the relation between
serum UA and BP. Although serum UA and BP showed
a significant relation in the overall population, when we
evaluated it according to different age groups (<40, 40–
59, ≥60), it was only significant in the non-elderly popu-
lation under age 60 in both genders. There have been
several studies suggesting that the strength of the rela-
tionship between serum UA and BP is more dominant
in the younger age groups and decreases during the aging
process as the duration of hypertension gets longerFigure 3 Serum uric acid levels in different age/gender groups. *Indicates
and hypertensive patients. (A) Men. (B) Women.[1,6,12,21-23]. However, none of the previous studies have
tried to investigate the effect of different age groups on
the relation as a primary goal. To our knowledge, this is
the first study to confirm the effect of different age groups
on the relation between serum UA and BP in a single large
cohort.
The prognostic significance of serum UA in different
disease entities such as diabetes, chronic kidney disease,
and cardiovascular diseases have been recognized in sev-
eral previous studies [2,5,6,9,24,25]. Understanding the
relationship between each diseases and serum UA has
been important due to the potential benefit which could
be achieved by applying it to new treatment strategies.
Feig et al. [16] mentioned that early hypertension devel-
oped in children and adolescents with hyperuricemia
could be reversed with urate reduction. Considering thegroups with significant differences (p < 0.05) between normotensive
Table 2 Multivariate linear regression analysis between blood pressure and uric acid
Groups Men Women
SBP DBP SBP DBP
β R2 p value β R2 p value β R2 p value β R2 p value
Total 0.33 0.10 <0.001 0.39 0.10 <0.001 0.61 0.19 <0.001 0.60 0.14 <0.001
<40 years 0.25 0.09 0.002 0.40 0.09 <0.001 0.54 0.05 <0.001 0.65 0.04 <0.001
40–59 years 0.29 0.06 0.03 0.43 0.05 <0.001 0.44 0.12 0.04 0.51 0.09 <0.001
≥60 years 0.57 0.05 0.05 0.34 0.03 0.08 −0.67 0.07 0.12 −0.26 0.04 0.35
Adjustment was done with age, diabetes, dyslipidemia, body mass index, and estimated glomerular filtration rate.
SBP systolic blood pressure, DBP diastolic blood pressure.
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results suggest the same could be applied beyond the
adolescent to the non-elderly adults under age 60 with
early hypertension and hyperuricemia.
There are several potential explanations for the attenu-
ation of the relationship in the elderly. Previous studies
implicating similar results have mentioned that the effect
of a single estimate of serum UA in the young may de-
crease over time, and the higher background rate of
hypertension incidence by other causes with increasing
age may contribute to the reduction of the strength of
the relationship between serum UA and BP [21]. Although
most of the studies controlled possible confounding vari-
ables such as age, BMI, and serum cholesterol levels, many
of them did not adjust for diabetes [6,25], antihypertensive
therapy [24-26], or diuretic use [25-27] which led to con-
troversial results regarding the relationship between
serum UA and BP, especially in the elderly. However, our
study initially was designed for complete control over the
variables mentioned above and excluded patients taking
medications possibly affecting serum UA levels and BP.
Variables such as age, BMI, diabetes, dyslipidemia, and
renal function, represented by eGFR, were all taken into
account for adjustment in the final analysis. Even after the
adjustments, the current study confirmed a significant
correlation with serum UA and BP in the non-elderly pa-
tients under age 60. Hyperuricemia increased the risk of
hypertension in both genders, but was only significant in
men <60 and women <40 in the multiple logistic regressionTable 3 Multivariate logistic regression analysis between
hyperuricemia and hypertension in different age/gender
groups
Groups Men Women
OR CI p value OR CI p value
Total 1.29 1.16–1.44 <0.001 1.35 0.99–1.84 0.06
<40 years 1.25 1.08–1.45 0.003 2.60 1.37–4.94 0.003
40–59 years 1.33 1.11–1.60 0.002 1.26 0.81–1.95 0.31
≥60 years 1.29 0.93–1.79 0.13 1.17 0.65–2.09 0.61
Adjustment was done with age, diabetes, dyslipidemia, body mass index, and
estimated glomerular filtration rate.
OR odds ratio, CI confidence interval.analysis. Particularly in women younger than 40 with hy-
peruricemia, our study demonstrated a 2.6-fold increase
in the risk of hypertension. Stronger association of serum
UA with BP and hypertension in women was seen, which
is in line with previous studies [6,23,28,29]. Awareness
and early interventional strategies in controlling hyperuri-
cemia associated with BP reduction in this specific group
may obtain maximal benefit.
Studies using animal models and cell cultures have
revealed mechanisms by which UA could cause hyper-
tension. In short, hypertension was developed by UA-
mediated renal vasoconstriction resulting from a reduction
in endothelial levels of nitric oxide, with activation of
renin-angiotensin system [30,31]. Microvascular renal dis-
ease independently was caused by UA over time, inducing
the development of hypertension [30].
Recent therapeutic trials with UA-lowering agents
have demonstrated promising results for reducing BP. In
one small study, the use of allopurinol, a xanthine
oxidase (XO) inhibitor, resulted in reduction of BP in
adolescents with newly diagnosed hypertension with hy-
peruricemia [16]. In another small study, UA-lowering
therapy with either allopurinol or probenecid, a uricosu-
ric agent, significantly reduced BP in prehypertensive,
obese, adolescents with hyperuricemia irrespective of the
UA-lowering mechanisms [32]. Allopurinol also showed
significant additional BP reduction when it was com-
bined with enalapril compared to enalapril alone in
hyperuricemic hypertensive adolescents [33]. There was
a report that a 6-month treatment of febuxostat, a more
recently developed selective XO inhibitor, showed a sig-
nificant BP reduction even in the elderly patients (mean
age, 67 ± 10.3 years) with serum UA ≥ 8 mg/dL in con-
trast to allopurinol [34]. Febuxostat had a stronger UA-
lowering effect and a renoprotective effect and was also
superior to allopurinol at inhibiting oxidative stress
atherogenesis, hypertension, and vascular endothelial
damage. However, the study was performed with an
intermediate size specific group who underwent cardiac
surgery, and 90% of the patients were already being
treated with antihypertensive therapy. Therefore, the ef-
fect of febuxostat on BP reduction may not be applicable
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elderly, yet.
Our study has several limitations. First, its cross-
sectional design could not reveal the causal role of serum
UA in the development of hypertension. Increased UA
levels at baseline are suggested to result in vascular dys-
function but after chronic exposure to high UA levels, the
corresponding alterations in the vasculature diminish over
time [35]. There may be an underlying genetic difference
between genders but the results of this study demonstrat-
ing a stronger association between UA and hypertension
in women than in men could have occurred due to the dif-
ference in the duration of exposure to elevated UA levels
[36]. Second, in contrast with previous studies [37], the
prevalence of hyperuricemia was highest in group <40. In
previous studies, the increasing prevalence of hyperurice-
mia in the elderly was because of higher incidence of tak-
ing antihypertensive and/or diuretic agents [7,17]. The
exclusion of these patients may have led to the results
above. Third, the statistical insignificance in the elderly
may have been due to the relatively smaller sample size
compared to the other groups. Fourth, with the exclusion
of subjects on antihypertensive medications, this may have
generated a bias in which our study results only regard
subjects with mild hypertension. However, our distinct
study design compared to previous observational studies
[24-27] in which we completely controlled medications af-
fecting serum UA levels may provide a more accurate in-
terpretation in the relationship between serum UA and
BP. Finally, we cannot absolutely exclude the possibility
that the study subjects were taking medications which
could affect serum UA levels or BP from family or friends
in secrecy because we only evaluated the medication his-
tory based on the legal prescriptions recorded by HIRA.
Conclusions
This single large cohort study confirmed that the rela-
tionship between serum UA and BP, hyperuricemia and
hypertension is quite different in each age group. In con-
trast to the elderly of 60 and over, the non-elderly
showed a significant association between serum UA and
BP in both genders. Hyperuricemia increased the relative
risk of hypertension by approximately 30% in men under
60 and by 2.6 fold in women under 40. We believe the
present study suggests specific age/gender groups which
would obtain maximal benefit from the treatment of hyper-
uricemia for the prevention and treatment of hypertension.
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